Clinical trials: Hemostatic Agents
Multiple Myeloma
Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)
Trial in patients with newly diagnosed myeloma to evaluate the effect of isatuximab in induction therapy with lenalidomide/bortezomib/dexamethasone (RVd) and in lenalidomide maintenance treatment
- Trial name
- NCT03617731
- Testing
- Lenalidomide, Bortezomib, Dexamethasone
- Where
- 72 sites in Germany
- Volunteers
- 662 people
- Sponsor
- University of Heidelberg Medical Center
Cerebral Cavernous Malformations
Treatments and Outcomes of Untreated Cerebral Cavernous Malformations in CHina.
This nationwide multicenter prospective cohort study will collect the treatment information and outcomes of the patients with previously untreated cavernous malformations (U-CMs) in China (at least 2000 patients from 20 centers).
- Trial name
- TOUCH (NCT03467295)
- Testing
- Surgery, Observation
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Multiple Myeloma
Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)
Bortezomib is an established treatment in multiple myeloma; it is common practice in the UK to administer bortezomib with dexamethasone. This practice is based on data that supports improved response rates with this combination.
- Trial name
- MUKfour (NCT01720875)
- Testing
- Vorinostat Velcade Dexamethasone
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- University of Leeds
Healthy Volunteers
Phase 1 Dosing Study of BAX 513 in Healthy Volunteers
The purpose of the study is to investigate whether orally administered BAX 513 (different doses administered for 5 days) affects hemostatic parameters in healthy volunteers.
- Trial name
- NCT01063101
- Testing
- Fucoidan (extract of Laminaria japonica)
- Where
- Austria
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Baxalta now part of Shire
Multiple Myeloma
A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment
The purpose of the study (Part 1 and Part 2) is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that…
- Trial name
- MagnetisMM-9 (NCT05014412)
- Testing
- Elranatamab
- Where
- 50 sites in United States, Japan and 2 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Kidney Cancer
Randomized Evaluation of Patients Who Have Had Laparoscopic Partial Nephrectomy
The purpose of this study is to evaluate the necessity of using hemostatic agents as a tool when performing robotic partial nephrectomy in the treatment of kidney cancer.
- Trial name
- NCT04120805
- Testing
- Hemostatic Agent, No Hemostatic Agent
- Where
- United States
- Volunteers
- 208 people
- Sponsor
- University of Chicago
Multiple Myeloma, Neoplasms
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
This is a phase 1/2, open-label study designed to assess the safety and clinical activity of different belantamab mafodotin doses in combination with lenalidomide, dexamethasone and nirogacestat in patients with transplant…
- Conditions
- Multiple Myeloma, Neoplasms, Neoplasm, Plasma Cell, Gammopathy, Monoclonal
- Trial name
- NCT05573802
- Testing
- Belantamab Mafodotin-Blmf, Lenalidomide, Dexamethasone
- Where
- 2 sites in Greece
- Volunteers
- 36 people
- Sponsor
- Hellenic Society of Hematology
Multiple Myeloma
MUK Nine b: OPTIMUM Treatment Protocol
To determine whether a combination of four novel agents bortezomib(Velcade), lenalidomide (Revlimid), Daratumumab (Darzalex) \& dexamethasone in combination with low-dose cyclophosphamide is sufficiently active in a high risk…
- Trial name
- MUKnineb (NCT03188172)
- Testing
- Cyclophosphamide, Bortezomib, Lenalidomide
- Where
- 21 sites in United Kingdom
- Volunteers
- 95 people
- Sponsor
- University of Leeds
Ehlers-Danlos Syndrome, Pain
Mind-Body Therapy for Pain in Ehlers-Danlos Syndrome
This study will assess the effectiveness of mind-body therapy in relieving pain in patients with Ehlers-Danlos syndrome. This syndrome is a hereditary condition caused by a connective tissue defect and is often associated with…
- Trial name
- NCT00001966
- Testing
- Mind-body therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Multiple Myeloma
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
Assess the impact in outcome of the use of zoledronic acid in multiple myeloma.
- Trial name
- NCT01234129
- Testing
- zoledronic acid
- Where
- Mexico
- Volunteers
- 320 people
- Sponsor
- Instituto Mexicano del Seguro Social
Inflammatory Bowel Diseases, Thromboembolism
Inflammatory Bowel Disease and Thromboembolic Events
The main objective was to demonstrate the existence and importance of hypercoagulability in patients with IBD, by determining the prevalence of changes in coagulation parameters and evaluating the impact of these changes on the…
- Conditions
- Inflammatory Bowel Diseases, Thromboembolism, Coagulation Disorder
- Trial name
- NCT05162339
- Testing
- No intervention was made
- Where
- Portugal
- Volunteers
- 149 people
- Sponsor
- Centro Hospitalar Tondela-Viseu
Multiple Myeloma
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
The purpose of this study is to evaluate the safety and efficacy of vaccination with autologous myeloma cells and an allogeneic granulocyte-macrophage colony stimulating factor (GM-CSF) producing cell line.
- Trial name
- NCT00116441
- Testing
- Therapeutic Cellular Vaccine, GM-CSF Producing
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Cell Genesys
Multiple Myeloma
The Molecular Characterization of Multiple Myeloma at Relapse
Observational study investigating prognostic factors in newly diagnosed and relapsed multiple myeloma patients by use of clinical data, biochemical markers (blood samples), cytogenetic markers and gene expression profiling…
- Trial name
- MM-FISH/DNA (NCT00639054)
- Testing
- Bone marrow examination, Blood samples
- Where
- Denmark
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Multiple Myeloma
Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
This is a Phase 2, open-label, multicenter study examining the safety, pharmacokinetics and pharmacodynamics, and best overall response to escalating doses of the proteasome inhibitor NPI-0052 (also known as marizomib) in…
- Trial name
- NCT00461045
- Testing
- MRZ 0.5 mg/m^2
- Where
- 6 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celgene
Multiple Myeloma, Refractory, Multiple Myeloma in Relapse
A Phase I Study to Assess the Tolerability of 225Ac-DOTATATE in Patients With Refractory and Relapsing Multiple Myeloma Expressing Somatostatin Receptors
This study aims to determine the safety and the recommended phase II dose of RYZ101 (actinium-225 labelled DOTA-octreotate (225Ac-DOTATATE)) in participants with refractory and relapsing multiple myeloma (MM) that have received…
- Conditions
- Multiple Myeloma, Refractory, Multiple Myeloma in Relapse, Multiple Myeloma Progression
- Trial name
- AcTRESS (NCT06411301)
- Testing
- 225Ac-DOTATATE
- Where
- Belgium
- Sponsor
- Jules Bordet Institute
Brain Cancer, Breast Cancer
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
This is an observational case-control study to train and validate a genome-wide methylome enrichment platform to detect multiple cancer types and to differentiate amongst cancer types.
- Conditions
- Brain Cancer, Breast Cancer, Bladder Cancer, Cervical Cancer
- Trial name
- CAMPERR (NCT05366881)
- Where
- 17 sites in United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- Adela, Inc
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Allogeneic ORCA-Q Stem Cell Transplant for the Treatment of Relapsed and Refractory High Risk Multiple Myeloma
This phase I trial tests the effect of allogeneic Orca-Q stem cell transplant in treating patients with high-risk multiple myeloma that has come back after a period of improvement (relapsed) or that has not responded to previous…
- Trial name
- NCT07759102
- Testing
- Allogeneic Defined Hematopoietic Stem Cells/Immune Cells, Busulfan, Filgrastim
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Davis
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM)
Multi-center, open-label, single-dose, dose-escalating Phase I/II study of GS 9219 in adult patients with relapsed or refractory CLL, NHL or MM. Patients will be enrolled into the study in sequential dose cohorts.
- Conditions
- Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma
- Trial name
- NCT00499239
- Testing
- GS-9219
- Where
- 20 sites in United States, Czechia and 1 more
- Volunteers
- 32 people
- Sponsor
- Gilead Sciences
Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
BCMA-Specific CAR T-Cells Combined With a Gamma Secretase Inhibitor (JSMD194) to Treat Relapsed or Persistent Multiple Myeloma
This phase I trial determines the side effects and best dose of B-cell maturation antigen (BCMA)-chimeric antigen receptor (CAR) T-cells when combined with gamma-secretase inhibitor LY3039478 (JSMD194), cyclophosphamide, and…
- Trial name
- NCT03502577
- Testing
- BCMA-specific CAR-expressing T Lymphocytes, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Fred Hutchinson Cancer Center
Waldenstrom Macroglobulinemia
Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia
Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally.
- Trial name
- RAINBOW (NCT04061512)
- Testing
- Dexamethasone, cyclophosphamide, rituximab, Rituximab, ibrutinib
- Where
- 25 sites in United Kingdom
- Volunteers
- 148 people
- Sponsor
- University College, London
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.